Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 10.00M | 15.00M | 15.00M | 15.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 10.00M | 15.00M | 15.00M | 15.00M |
| Cost of Revenue | 193.59M | 168.06M | 161.50M | 160.63M | 151.41M |
| Gross Profit | -193.59M | -158.06M | -146.50M | -145.63M | -136.41M |
| SG&A Expenses | 57.82M | 53.32M | 49.20M | 43.47M | 37.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 251.41M | 221.39M | 210.70M | 204.10M | 188.64M |
| Operating Income | -251.41M | -211.39M | -195.70M | -189.10M | -173.64M |
| Income Before Tax | -425.03M | -377.82M | -189.66M | -176.76M | -162.54M |
| Income Tax Expenses | 126.00K | -79.00K | 244.00K | 244.00K | 224.00K |
| Earnings from Continuing Operations | -425.15 | -377.74 | -189.90 | -177.01 | -162.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -425.15M | -377.74M | -189.90M | -177.01M | -162.76M |
| EBIT | -251.41M | -211.39M | -195.70M | -189.10M | -173.64M |
| EBITDA | -251.37M | -211.33M | -195.62M | -189.00M | -173.51M |
| EPS Basic | -8.46 | -7.81 | -4.53 | -8.32 | -31.30 |
| Normalized Basic EPS | -3.25 | -2.84 | -2.75 | -5.20 | -19.56 |
| EPS Diluted | -8.46 | -7.81 | -4.53 | -8.32 | -31.30 |
| Normalized Diluted EPS | -3.25 | -2.84 | -2.75 | -5.20 | -19.56 |
| Average Basic Shares Outstanding | 192.65M | 178.83M | 167.76M | 133.30M | 93.00M |
| Average Diluted Shares Outstanding | 192.65M | 178.83M | 167.76M | 133.30M | 93.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |